The growing focus on biopharmaceutical safety, quality assurance, and contamination prevention is significantly accelerating expansion within the global Mycoplasma Testing Market. Mycoplasma contamination remains a major challenge in cell culture research, vaccine production, and biologics manufacturing because these microorganisms can alter cellular activity and compromise research accuracy without visible signs of contamination.

According to the Polaris Market Research report, the global Mycoplasma Testing Market was valued at USD 1.36 Billion in 2025 and is projected to reach USD 4.3 Billion by 2034, registering a CAGR of 13.50% during 2025–2034.

One of the primary factors driving market growth is the increasing demand for biologics, cell therapies, and vaccines. Biopharmaceutical companies rely heavily on contamination-free cell cultures during research and manufacturing processes. Mycoplasma contamination can negatively impact product quality, reduce production efficiency, and create regulatory compliance challenges, making routine testing essential across pharmaceutical and biotechnology industries.

The increasing adoption of cell-based research and regenerative medicine is further contributing to growth in the Mycoplasma Testing Market. Stem cell therapies, monoclonal antibodies, gene therapies, and tissue engineering applications require highly controlled laboratory environments to ensure research integrity and patient safety. As advanced biologic therapies continue expanding globally, demand for reliable mycoplasma testing solutions is expected to increase significantly.

PCR-based testing methods accounted for the largest market share in 2024 because of their high sensitivity, accuracy, and rapid turnaround time. Polymerase chain reaction technologies enable laboratories to detect mycoplasma contamination quickly and efficiently, supporting faster quality control procedures in pharmaceutical manufacturing and research applications. The increasing preference for rapid microbial testing technologies is helping accelerate adoption of molecular diagnostic solutions.

The pharmaceutical and biotechnology companies segment dominated the market in 2024 due to stringent regulatory requirements regarding contamination control in biologics production. Regulatory agencies worldwide continue implementing strict quality assurance guidelines that require routine mycoplasma testing throughout drug development and manufacturing workflows. Compliance with these regulations remains critical for maintaining product safety and commercial approval.

Read More @ https://www.polarismarketresearch.com/industry-analysis/mycoplasma-testing-market

Technological advancements are also playing a major role in supporting market expansion. Companies are introducing automated testing systems, advanced PCR platforms, and highly sensitive detection assays that improve testing efficiency and laboratory productivity. Automation technologies are helping reduce human error, improve throughput capacity, and streamline quality control operations across research and manufacturing facilities.

The growing outsourcing of biologics manufacturing and contract research activities is another important factor driving demand for mycoplasma testing services. Contract research organizations and contract manufacturing organizations increasingly require robust contamination testing solutions to maintain regulatory compliance and ensure production quality for pharmaceutical clients.

North America accounted for the largest share of the Mycoplasma Testing Market in 2024 due to advanced biopharmaceutical infrastructure, strong research funding, and increasing biologics production activities. The region benefits from the presence of leading biotechnology companies and highly developed healthcare research ecosystems. Europe also represents a significant market because of growing pharmaceutical innovation and regulatory emphasis on biologics safety. Asia Pacific is expected to witness substantial growth during the forecast period owing to expanding biotechnology industries, rising research investments, and increasing pharmaceutical manufacturing activities.

Key companies operating in the Mycoplasma Testing Market include Thermo Fisher Scientific Inc., Lonza Group AG, Merck KGaA, and Charles River Laboratories International, Inc.. These companies are focusing on advanced assay development, laboratory automation, and strategic partnerships to strengthen their market positions.

As biologics production and cell-based research continue expanding globally, the Mycoplasma Testing Market is expected to witness sustained long-term growth driven by increasing demand for contamination-free laboratory and manufacturing environments.

More Trending Latest Reports By Polaris Market Research:

Recruitment Process Outsourcing Market

Enhanced Due Diligence Market

Warehouse Automation Market

Non-specific Endonucleases Market

Neurology Clinical Trials Market

Veterinary Chemistry Analyzer Market

Hemostasis Valve Market

PVC And CPVC Pipe Fittings Market

Pharmacy Automation Market